Farmas USA

Buenas tardes,

http://moneymorning.com/2015/07/24/chart-pharma-companies-make-billions-as-prescription-spending-soars/

Calentando al sector Farmas...

Yo entré a 1,73...
A tener paciencia y a confiar en los resltados clínicos de octubre....

GALE

NYMX

Qué sí, que sí, Ana y Framus, que lo que dije es que me gusta NYMX para una subida, pero que hoy estaré pendiente y que espero que los cortos hagan su escabechina pero bien hecha, y entonces, p'a dentro.

GALE

Gracias por el dato, la sigo de cerca.

IMMU

No estoy para meterme en otra de infarto, jajaja.

FORO

Hoy lo estoy leyendo todo ¿eh?, jejeje.

NAVB

Le dan pasta para un estudio de fase I. Algo es algo.

Navidea Biopharma (NAVB) Receives $321k SBIR Phase 1 Grant

Navidea Biopharma (NYSE: NAVB) announced the receipt of a notice of award for a Phase 1 Small Business Innovation Research (SBIR) grant providing $321K from the National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH). The study, to be done in collaboration with Massachusetts General Hospital (MGH) and Harvard Medical School, will examine the ability of Tc 99m-tilmanocept, a Manocept™ platform product, to localize in high-risk atherosclerotic plaques. These specific plaques are rich in CD206 expressing macrophages and are at high-risk for near term rupture resulting in myocardial infarctions, sudden cardiac death and strokes, accumulatively the leading cause of death in the US.

The consequences of atherosclerosis and the cardiovascular disease (CVD) that atherosclerosis causes, while severe in all populations of people, are particularly concentrated in HIV+ patients. “This Phase 1 pilot study may provide evidence that Tc99m-tilmanocept localizes in atherosclerotic plaques which would enable potential development of a diagnostic imaging agent that could benefit not only HIV+ patients but millions of people,” said Michael Tomblyn, M.D., Navidea’s Chief Medical Officer. “Positive outcomes would also support our Manocept development vision of a larger program that seeks to evaluate tilmanocept as a targeting vehicle to deliver therapies intended to limit or reverse atherosclerosis directly to plaques that could reduce cardiovascular disease (CVD) risk and improve outcomes for this patient population.”

“HIV infected patients suffer disproportionally from atherosclerosis and CVD,” commented Steven Grinspoon, M.D., Professor of Medicine at Harvard Medical School, Director MGH Program in Nutritional Metabolism, Co-Director of the Nutrition Obesity Research Center at Harvard and the study’s lead investigator. “There exists a profound and highly significant unmet need for means to better diagnose and treat atherosclerosis in all patients but particularly so in HIV patients. Manocept’s proven specificity for CD206 presents a clinically exploitable target with potential to achieve significant diagnostic and therapeutic results where few other approaches have progressed.”

NYMX

Ana, Framus.. muchas gracias por los consejos...

Yo ya vendí y, a priori, listo.. hoy la voy a seguir.. Es cierto que sí que creo que podría seguir escalando, hasta los 4 dólares... pero también tenía claro que había que saltar del barco...

Feliz tarde,

Solofarmas Gale tiene que presentar datos finales de anagrelide, eso será en diciembre seguro, en el Americano de Hematología y también los finales de la vacuna 301 que yo sepa fecha no dan, seguramente finales de año, y por último Neuvax en el último cuarto de este año o bien el primero del siguiente, lo de Octubre lo sacas de algún lado?
GALE

El otro día lo encontré y lo publiqué en el foro, y creo que Ana se guardo la info...
Yo me olvidé de guardarlo, y ahora no lo encuentro....
Ana, guardastes la info de GALE, verdad?

CYTX

Creo que va a dar para una subida interesante para los que compraron los últimos días.

Mola la noticia, pero no me mola lo de que una empresa privada ya tenga los derechos. Siempre hablamos de los partenings y los BO, pero cuando una empresa la vuelven privada los accionistas nos quedamos con la miel en los labios. Hay casos.

Kerastem Technologies, a wholly owned subsidiary of Bimini Technologies, received U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to conduct a clinical trial studying the safety and feasibility of its technology for the treatment of female and early male pattern baldness (androgenic alopecia).

STYLE is a 70 patient controlled trial that is expected to begin enrollment in late 2015 at up to eight (8) centers within the United States. The primary endpoint is safety and tolerability of the treatment and secondary endpoints include change in hair growth and density.

In 2013, Bimini, a private medical technology company, acquired global and exclusive rights to commercialize Cytori Celution® Technology for alopecia and hair related indications. Under the commercial agreement, Bimini will be responsible for all key activities including clinical studies, regulatory approvals, and market development. Bimini will acquire Cytori products at agreed upon transfer pricing and pay Cytori a perpetual royalty on sales.